|1.||Lip, Gregory Y H: 3 articles (01/2007 - 01/2006)|
|2.||Bay, R Curtis: 2 articles (11/2015 - 11/2006)|
|3.||Hogg, Ronald J: 2 articles (11/2015 - 11/2006)|
|4.||Calder, Philip C: 2 articles (08/2015 - 10/2014)|
|5.||Scorletti, Eleonora: 2 articles (08/2015 - 10/2014)|
|6.||McCormick, Keith G: 2 articles (08/2015 - 10/2014)|
|7.||Clough, Geraldine F: 2 articles (08/2015 - 10/2014)|
|8.||Byrne, Christopher D: 2 articles (08/2015 - 10/2014)|
|9.||Bhatia, Lokpal: 2 articles (08/2015 - 10/2014)|
|10.||Rupp, Heinz: 2 articles (07/2009 - 12/2006)|
01/01/2006 - "Three-month supplementation of Omacor at 1 g per day in post-MI patients is not associated with an improvement in the levels of peripheral indices of coagulation potential, endothelial function, platelet reactivity and inflammation."
02/01/2011 - "A number of novel therapeutic agents have also been tested in db/db mice, including inhibitors of inflammation (chemokine receptor antagonists, anti-CCL2 RNA aptamer, anti-c-fms antibody); oxidative stress (oxykine, biliverdin); the renin-angiotensin-aldosterone system (aliskiren, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, eplerenone); advanced glycation end products (AGE; pyridoxamine, alagebrium, soluble AGE receptor); angiogenesis (NM-3, anti-CXCL12 RNA aptamer, soluble Flt-1); lipid accumulation (statins, farnesoid X receptor agonists, Omacor); intracellular signaling pathways (PKC-β or JNK inhibitors); and fibrosis [transforming growth factor (TGF)-β antibody, TGF-βR kinase inhibitor, soluble betaglycan, SMP-534, CTGF-antisense oligonucleotide, mutant PAI-1, pirfenidone], which have identified potential therapeutic targets for clinical translation. "
|2.||Liver Cirrhosis (Hepatic Cirrhosis)
|3.||Body Weight (Weight, Body)
07/01/2012 - "This study shows that early life ARA/DHA, but not Omacor supplementation improves body weight gain later in life. "
07/01/2012 - "Omacor had no significant effect on body weight gain. "
09/01/2006 - "Conversely, increasing levels of lipid parameters were observed with increasing dosages of Omacor (EPA+DHA) in grams per kilogram of body weight at 6 wk of treatment. "
11/01/2006 - "A similar relationship was observed between urine protein/creatinine ratio and dosage of Omacor per kilogram of body weight in trial 2 (r = -0.38, P < 0.001). "
09/01/2006 - "Parameters included body weight; body mass index (BMI); plasma phospholipid AA, EPA, and docosahexanoic acid (DHA) levels and serum creatinine and 24-h urine protein (UP) levels during the 2-yr trial; and time to ESRD after 6.4 yr. Plasma phospholipid levels of EPA, DHA, and EPA/AA ratios were significantly inversely correlated with increasing body weight and BMI in the Omacor 4-g dosage group but not in the Omacor 8-g dosage group. "
07/01/2009 - "At higher dosages (daily, 3-4 g) Omacor exhibits more pronounced cardiovascular benefits and, as a licensed indication, improves hypertriglyceridemia and related lipid parameters."
08/21/2006 - "Omacor provides a safe, effective, well-tolerated approach to management of hypertriglyceridemia."
07/01/2007 - "This study evaluated the effects on non-HDL-C and other variables of adding prescription omega-3-acid ethyl esters (P-OM3; Lovaza, formerly Omacor [Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey]) to stable statin therapy in patients with persistent hypertriglyceridemia. "
07/01/2009 - "Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia."
11/07/2005 - "Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia."
|5.||IGA Glomerulonephritis (IGA Nephropathy)
09/01/2006 - "Omacor also was used in the North American IgA Nephropathy Study. "
09/01/2006 - "Data from a previously reported randomized 2-yr clinical trial in which two dosages of an ethyl ester omega-3 PUFA (Omacor) were given to 73 high-risk patients with IgA nephropathy were reviewed. "
11/01/1996 - "This includes a brief description of a three-arm multicenter, placebo-controlled study evaluating alternate-day prednisone and highly purified fish oil concentrate (Omacor) in children and young adults with moderately severe forms of IgA nephropathy."
02/01/2004 - "Twenty-three adult patients with biopsy proven IgA nephropathy, with proteinuria more than 1 g/day, serum creatinine less than 3 mg/dl and blood pressure control less than 130/80 mmHg were given omega-3 polyunsaturated fatty acids (PUFA) in the form of an Omacor capsule 4 g/day equivalent to eicosapentaenoic acid (EPA) 1.88 g and docosahexaenoic acid (DHA) 1.48 g for 6 months. "
|3.||Omega-3 Fatty Acids (Omega 3 Fatty Acids)
|5.||Arachidonic Acid (Vitamin F)
|7.||Cholecalciferol (Vitamin D3)
|8.||Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)
|1.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
|2.||Investigational Therapies (Experimental Therapy)